The company said sales from continuing operations for Q4 2025 were $2.97 billion, up 8% on a reported basis and 3% on an operational basis, and that adjusted diluted EPS was $0.44, down 24% from $0.58 a year earlier.

1. 01

   The company said sales from continuing operations for Q4 2025 were $2.97 billion, up 8% on a reported basis and 3% on an operational basis, and that adjusted diluted EPS was $0.44, down 24% from $0.58 a year earlier.

2. 02

   The company said its U.S. GAAP diluted loss per share from continuing operations for Q4 was ($2.01), including a goodwill impairment charge of $485 million related to the Front Line Care reporting unit and a valuation allowance on U.S. deferred tax assets of $330 million.

3. 03

   Baxter said it expects full-year 2026 reported sales growth from continuing operations of flat to 1%, organic sales growth of approximately flat, and adjusted diluted EPS from continuing operations of $1.85 to $2.05.

4. 04

   The company said it appointed Michael R. McDonnell to its board of directors effective February 13, 2026, and that Cathy R. Smith and Stephen H. Rusckowski resigned from the board on the same day, leaving the board with 10 directors. It also set a quarterly cash dividend of $0.01 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.